Laboratory blood parameters and machine learning for the prognosis of esophageal squamous cell carcinoma
Frontiers in Oncology · 03.04.2024 · 14
DOI: 10.3389/fonc.2024.1367008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 03.04.2024. Verfasst von Feng Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, The People's Hospital of Jianyang City, Jianyang, Sichuan, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In contemporary study, the death of esophageal squamous cell carcinoma (ESCC) patients need precise and expedient prognostic methodologies.
Objective
To develop and validate a prognostic model tailored to ESCC patients, leveraging the power of machine learning (ML) techniques and drawing insights from comprehensive datasets of laboratory-derived blood parameters.
Methods
Three ML approaches, including Gradient Boosting Machine (GBM), Random Survival Forest (RSF), and the classical Cox method, were employed to develop models on a dataset of 2521 ESCC patients with 27 features. The models were evaluated by concordance index (C-index) and time receiver operating characteristics (Time ROC) curves. We used the optimal model to evaluate the correlation between features and prognosis and divide patients into low- and high-risk groups by risk stratification. Its performance was analyzed by Kaplan-Meier curve and the comparison with AJCC8 stage. We further evaluate the comprehensive effectiveness of the model in ESCC subgroup by risk score and KDE (kernel density estimation) plotting.
Results
RSF’s C-index (0.746) and AUC (three-year AUC 0.761, five-year AUC 0.771) had slight advantage over GBM and the classical Cox method. Subsequently, 14 features such as N stage, T stage, surgical margin, tumor length, age, Dissected LN number, MCH, Na, FIB, DBIL, CL, treatment, vascular invasion, and tumor grade were selected to build the model. Based on these, we found significant difference for survival rate between low-(3-year OS 81.8%, 5-year OS 69.8%) and high-risk (3-year OS 25.1%, 5-year OS 11.5%) patients in training set, which was also verified in test set (all P < 0.0001). Compared with the AJCC8th stage system, it showed a greater discriminative ability which is also in good agreement with its staging ability.
Conclusion
We developed an ESCC prognostic model with good performance by clinical features and laboratory blood parameters.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Medicine, The People's Hospital of Jianyang City, Jianyang, Sichuan, China.
- College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Transfusion Medicine, West China Hospital, Sichuan University, Chengdu, China.
- Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology o…
- Outpatient Department, People's Hospital of Jianyang, Jianyang, Sichuan, China.
- Department of Clinical Laboratory, Chuankong Hospital of Jianyang, Jianyang, Sichuan, China.
Zitieren
APA
Lu, F., Yang, L., Luo, Z., He, Q., Shangguan, L., Cao, M., & Wu, L. (2024). Laboratory blood parameters and machine learning for the prognosis of esophageal squamous cell carcinoma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1367008
Vancouver
Lu F, Yang L, Luo Z, He Q, Shangguan L, Cao M, et al. Laboratory blood parameters and machine learning for the prognosis of esophageal squamous cell carcinoma. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1367008
BibTeX
@article{Lu2024,
author = {Lu, Feng and Yang, Linlan and Luo, Zhenglian and He, Qiao and Shangguan, Lijuan and Cao, Mingfei and Wu, Lichun},
title = {Laboratory blood parameters and machine learning for the prognosis of esophageal squamous cell carcinoma},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1367008}
}
EUVIMED